171 related articles for article (PubMed ID: 37429411)
21. Changes in the susceptibility of Bacteroides fragilis group organisms to various antimicrobial agents 1979-1989.
Betriu C; Cabronero C; Gomez M; Picazo JJ
Eur J Clin Microbiol Infect Dis; 1992 Apr; 11(4):352-6. PubMed ID: 1396757
[TBL] [Abstract][Full Text] [Related]
22. Comparative Genomics of Bacteroides fragilis Group Isolates Reveals Species-Dependent Resistance Mechanisms and Validates Clinical Tools for Resistance Prediction.
Wallace MJ; Jean S; Wallace MA; Burnham CD; Dantas G
mBio; 2022 Feb; 13(1):e0360321. PubMed ID: 35038926
[TBL] [Abstract][Full Text] [Related]
23. [Bacteroides fragilis group in non-diarrheal human feces and its antimicrobial susceptibility].
Rodríguez E; Gamboa MM; Rodríguez C; Vargas P
Rev Esp Quimioter; 2006 Dec; 19(4):357-62. PubMed ID: 17235405
[TBL] [Abstract][Full Text] [Related]
24. Longitudinal study of susceptibilities of species of the Bacteroides fragilis group to five antimicrobial agents in three medical centers.
Turgeon P; Turgeon V; Gourdeau M; Dubois J; Lamothe F
Antimicrob Agents Chemother; 1994 Oct; 38(10):2276-9. PubMed ID: 7840557
[TBL] [Abstract][Full Text] [Related]
25. [ESBL-positive strains of the Bacteroides fragilis group isolated from patients at the regional hospital center in Płock (Poland)].
Rokosz A; Pawłowska J; Sawicka-Grzelak A; Luczak M
Med Dosw Mikrobiol; 2004; 56(3):245-53. PubMed ID: 15773501
[TBL] [Abstract][Full Text] [Related]
26. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe.
Hedberg M; Nord CE;
Clin Microbiol Infect; 2003 Jun; 9(6):475-88. PubMed ID: 12848722
[TBL] [Abstract][Full Text] [Related]
27. First national survey of antibiotic susceptibility of the Bacteroides fragilis group: emerging resistance to carbapenems in Argentina.
Fernández-Canigia L; Litterio M; Legaria MC; Castello L; Predari SC; Di Martino A; Rossetti A; Rollet R; Carloni G; Bianchini H; Cejas D; Radice M; Gutkind G;
Antimicrob Agents Chemother; 2012 Mar; 56(3):1309-14. PubMed ID: 22232282
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of antibiotic susceptibility of Bacteroides, Prevotella and Fusobacterium species isolated from patients of the N. N. Blokhin Cancer Research Center, Moscow, Russia.
Shilnikova II; Dmitrieva NV
Anaerobe; 2015 Feb; 31():15-8. PubMed ID: 25157873
[TBL] [Abstract][Full Text] [Related]
29. Evolution of antimicrobial susceptibility in isolates of the Bacteroides fragilis group in Spain.
García-Rodríguez JE; García-Sánchez JE
Rev Infect Dis; 1990; 12 Suppl 2():S142-51. PubMed ID: 2305180
[TBL] [Abstract][Full Text] [Related]
30. In vitro activities of clindamycin, imipenem, metronidazole, and piperacillin-tazobactam against susceptible and resistant isolates of Bacteroides fragilis evaluated by kill kinetics.
Schaumann R; Funke M; Janssen E; Rodloff AC
Antimicrob Agents Chemother; 2012 Jun; 56(6):3413-6. PubMed ID: 22430962
[TBL] [Abstract][Full Text] [Related]
31. Occurrence of metronidazole and imipenem resistance among Bacteroides fragilis group clinical isolates in Hungary.
Nagy E; Sóki J; Urban E; Szoke I; Fodor E; Edwards R
Acta Biol Hung; 2001; 52(2-3):271-80. PubMed ID: 11426861
[TBL] [Abstract][Full Text] [Related]
32. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience.
Nagy E; Urbán E; Nord CE;
Clin Microbiol Infect; 2011 Mar; 17(3):371-9. PubMed ID: 20456453
[TBL] [Abstract][Full Text] [Related]
33. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).
Snydman DR; Jacobus NV; McDermott LA; Golan Y; Hecht DW; Goldstein EJ; Harrell L; Jenkins S; Newton D; Pierson C; Rihs JD; Yu VL; Venezia R; Finegold SM; Rosenblatt JE; Gorbach SL
Clin Infect Dis; 2010 Jan; 50 Suppl 1():S26-33. PubMed ID: 20067390
[TBL] [Abstract][Full Text] [Related]
34. Prevalence and antimicrobial susceptibility of enterotoxigenic extra-intestinal Bacteroides fragilis among 13-year collection of isolates in Kuwait.
Jamal W; Khodakhast FB; AlAzmi A; Sόki J; AlHashem G; Rotimi VO
BMC Microbiol; 2020 Jan; 20(1):14. PubMed ID: 31941446
[TBL] [Abstract][Full Text] [Related]
35. High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan.
Teng LJ; Hsueh PR; Tsai JC; Liaw SJ; Ho SW; Luh KT
Antimicrob Agents Chemother; 2002 Sep; 46(9):2908-13. PubMed ID: 12183246
[TBL] [Abstract][Full Text] [Related]
36. Phenotypic and Genotypic Correlation of Antimicrobial Susceptibility of Bacteroides fragilis: Lessons Learnt.
Jha L; Y BL; Ragupathi NKD; Veeraraghavan B; Prakash JAJ
Cureus; 2023 Mar; 15(3):e36268. PubMed ID: 37073211
[TBL] [Abstract][Full Text] [Related]
37. Comparative evaluation of agar dilution and broth microdilution by commercial and in-house plates for Bacteroides fragilis group: An economical and expeditious approach for resource-limited settings.
Sood A; Angrup A; Ray P; Bala K
Anaerobe; 2021 Oct; 71():102443. PubMed ID: 34492368
[TBL] [Abstract][Full Text] [Related]
38. Trends and Impact in Antimicrobial Resistance Among
Kierzkowska M; Majewska A; Mlynarczyk G
Microb Drug Resist; 2020 Dec; 26(12):1452-1457. PubMed ID: 32407191
[No Abstract] [Full Text] [Related]
39. Susceptibility of 114 isolates of the Bacteroides fragilis group to imipenem and eight other antimicrobial agents.
Downes J; Andrew JH
Pathology; 1988 Jul; 20(3):260-3. PubMed ID: 3205597
[TBL] [Abstract][Full Text] [Related]
40. Inducible metronidazole resistance in nim-positive and nim-negative bacteroides fragilis group strains after several passages metronidazole containing columbia agar plates.
Schaumann R; Petzold S; Fille M; Rodloff AC
Infection; 2005 Oct; 33(5-6):368-72. PubMed ID: 16258869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
